<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604708</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-301</org_study_id>
    <nct_id>NCT00604708</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of the Japanese Encephalitis Vaccine IC51</brief_title>
  <official_title>Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51
      compared to JE-VAX in healthy subjects aged &gt; or = 18 years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>SCR: anti-JEV neutralizing antibody titer â‰¥1:10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT (Geometric Mean Titer) of IC51 Compared to JE-VAX at Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>GMT: geometric mean of PRNT50</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Adverse Events</measure>
    <time_frame>until Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity at Day 56 for North America vs. Europe</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity at Day 56 for Subjects Older vs. Younger Than 50 Years of Age</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">867</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>IC51</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JE-VAX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>given s.c. on Day 0, 7 and 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51</intervention_name>
    <description>IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28</description>
    <arm_group_label>IC51</arm_group_label>
    <other_name>Japanese Encephalitis purified inactivated vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JE-VAX</intervention_name>
    <description>JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28</description>
    <arm_group_label>JE-VAX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Written informed consent obtained prior to study entry

        Exclusion Criteria:

          -  History of clinical manifestation of any flavivirus infection

          -  History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue
             fever (an anti-JEV neutralizing antibody titer &gt;= 1:10 at baseline is acceptable for
             inclusion, these subjects will be part of the safety population, but will not be
             analyzed for immunogenicity in the per-protocol analysis)

          -  Use of any other investigational or non-registered drug or vaccine in addition to the
             study vaccine during the study period or within 30 days preceding the first dose of
             study vaccine

          -  Immunodeficiency including post-organ-transplantation or immunosuppressive therapy

          -  A family history of congenital or hereditary immunodeficiency

          -  History of autoimmune disease

          -  Any acute infections within 4 weeks prior to enrollment

          -  Infection with HIV, Hepatitis B or Hepatitis C

          -  Pregnancy, lactation or unreliable contraception in female subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Kaltenboeck, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>May 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2012</results_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IC51</title>
          <description>IC51</description>
        </group>
        <group group_id="P2">
          <title>JE-VAX</title>
          <description>JE-VAX</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="430"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IC51</title>
          <description>IC51</description>
        </group>
        <group group_id="B2">
          <title>JE-VAX</title>
          <description>JE-VAX</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="430"/>
            <count group_id="B2" value="437"/>
            <count group_id="B3" value="867"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="14.5"/>
                    <measurement group_id="B2" value="41.1" spread="14.4"/>
                    <measurement group_id="B3" value="41.3" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56</title>
        <description>SCR: anti-JEV neutralizing antibody titer â‰¥1:10</description>
        <time_frame>Day 56</time_frame>
        <population>Per Protocol Population: all randomized subjects without any protocol deviations as defined in the Statistical Analysis Plan</population>
        <group_list>
          <group group_id="O1">
            <title>IC51</title>
            <description>IC51</description>
          </group>
          <group group_id="O2">
            <title>JE-VAX</title>
            <description>JE-VAX</description>
          </group>
        </group_list>
        <measure>
          <title>SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56</title>
          <description>SCR: anti-JEV neutralizing antibody titer â‰¥1:10</description>
          <population>Per Protocol Population: all randomized subjects without any protocol deviations as defined in the Statistical Analysis Plan</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                    <measurement group_id="O2" value="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Adverse Events</title>
        <time_frame>until Day 56</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity at Day 28</title>
        <time_frame>Day 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity at Day 56 for North America vs. Europe</title>
        <time_frame>Day 56</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity at Day 56 for Subjects Older vs. Younger Than 50 Years of Age</title>
        <time_frame>Day 56</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMT (Geometric Mean Titer) of IC51 Compared to JE-VAX at Day 56</title>
        <description>GMT: geometric mean of PRNT50</description>
        <time_frame>Day 56</time_frame>
        <population>PP Population: All randomized subjects without any major protocol deviations as assessed during a Data Review Meeting. Subjects who were randomized incorrectly or took the wrong study medications were also excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>IC51</title>
            <description>IC51</description>
          </group>
          <group group_id="O2">
            <title>JE-VAX</title>
            <description>JE-VAX</description>
          </group>
        </group_list>
        <measure>
          <title>GMT (Geometric Mean Titer) of IC51 Compared to JE-VAX at Day 56</title>
          <description>GMT: geometric mean of PRNT50</description>
          <population>PP Population: All randomized subjects without any major protocol deviations as assessed during a Data Review Meeting. Subjects who were randomized incorrectly or took the wrong study medications were also excluded.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.6" spread="1163.1"/>
                    <measurement group_id="O2" value="102" spread="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>numbers provided for safety population (N= 863)</desc>
      <group_list>
        <group group_id="E1">
          <title>IC51</title>
          <description>IC51</description>
        </group>
        <group group_id="E2">
          <title>JE-VAX</title>
          <description>JE-VAX</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Influenza like Ilness</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager Clinical Research</name_or_title>
      <organization>Intercell AG</organization>
      <phone>+43 1 206 20 ext 1175</phone>
      <email>kdubischar-kastner@intercell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

